Company Name: LBT Innovations
Announcement Date: 01/09/2016
Announcement Category: Other, Team Update
Announcement Content:
Financial Highlights
Revenue for the year to 30 June 2016 was $7.73 million (up from $2.37 million for the year ended
30 June 2015).
Revenue consisted of:
$7.52 million from the proceeds from bioMérieux’s termination of the original MicroStreak licence
agreement and the granting to bioMérieux a new non-exclusive licence;
Interest revenue of $115,000 (up from $43,000 for the year ended 30 June 2015);
The recognition of deferred commercial ready grant income of $141,000 (consistent with the year
ended 30 June 2015);
Income recognised of $115,000 from a BioSA grant (total grant approved of $250,000);
Consulting income of $138,000 relating to recoveries from the JV entity, CCS in Switzerland;
Less royalty income adjustments and foreign exchange loss ($301,000).
The cash position as at 30 June 2016 was $4.68 million (2015 $1.82 million).
LBT Innovations Ltd received an R&D tax concession refund of $1.62 million following completion of
the 2015 tax return. The Company will lodge a claim for the 2016 year with an estimated cash refund
of approximately $1.3 million.
Announcement URL: http://www.lbtinnovations.com/assets/Uploads/Preliminary-Final-Report.pdf
About LBT Innovations:
Over the past decade, LBT Innovations has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories.
Go to Company Profile for: LBT Innovations
Announcement Contact: [email protected]
